Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT01991587

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent Virus-like-particle (VLP) Influenza Vaccine in Adults

Sponsor: Medicago

Conditions RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Interventions High dose of quadrivalent VLP vaccine Low dose of quadrivalent VLP vaccine Medium dose of quadrivalent VLP vaccine Placebo

Updated 8 times since 2017 Last updated: Jun 8, 2020 Started: Oct 8, 2013 Primary completion: Jun 30, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on RNA Virus Infections and Respiratory Tract Diseases, this trial is completed. The trial is conducted by Medicago and has accumulated 8 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jul 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Dec 2019 — Jul 2020 [monthly]

Completed PHASE1_PHASE2

▶ Show 3 earlier versions

Jun 2018 — Dec 2019 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medicago

Data source: Medicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States